BLIS announces new board member

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz



NZX Release
BLIS announces new board member
Blis Technologies Limited, 28 September 2018, Dunedin, NZ
Blis Technologies Limited (NZX: BLT) advises the appointment of Dr Alison Stewart as an independent
director of the company with effect from 28 September 2018.
Dr Stewart brings to the board governance and commercial experience within the international
biotech industry. Dr Stewart has held key executive leadership roles in New Zealand and US corporates
and understands the drivers for commercial success. Alison has experience with patents, IP protection,
new product pipeline and development of strategic partnerships with large international corporations.
Dr Stewart is currently Chief Executive Officer of the Foundation of Arable Research and in previous
roles has lead research teams across NZ, Australia and the USA. Alison is a Distinguished Emeritus
Professor, Lincoln University, NZ and received a Queens Birthday Honours Companion of the NZ Order
of Merit award in 2011.
Chairman Tony Offen said “We are delighted Dr Stewart has agreed to join the board and believe her
commercial background underpinned by her academic qualifications will add considerable value to
the company.”
The company’s focus remains growing revenues and consumer reach for its branded product range
across core markets whilst developing international partnerships that are capable of accelerating
growth by leveraging the company’s brand, IP and pipeline opportunities.
The new appointment is the result of a director search undertaken as part the board’s succession
planning. The board has determined that Dr Stewart will be an independent director and will support
her when formally offering herself for election as director at the next annual shareholders' meeting in
July 2019.
About Blis Technologies Ltd
Blis Technologies is the developer of the world’s first advanced oral probiotics. Developed in New
Zealand and backed by more than 30 years of research, the BLIS range includes products that support
oral, ear, nose and throat health. BLIS probiotics were discovered by Professor John Tagg while
working as a researcher at the University of Otago Microbiology Department. BLIS products are sold
throughout New Zealand and in Asia, Europe, and USA.

Tony Offen
Chair
Blis Technologies Limited